Srishti Chakravorty

Postdoctoral Research Scientist @Merck

San Francisco, CA, US
MOBILE NUMBERS
+17•••••••03

Signup · Get unlimited contacts

WORK HISTORY

Oct 2022 — Present

Postdoctoral Research Scientist @Merck

View department →

South San Francisco, CA, US

Tumor Model Development: Designed and validated predictive murine tumor models to evaluate multiple ADC candidates.• Molecular TME Analysis: Analyzed molecular changes within the tumor microenvironment (TME) in response to ADC payloads; findings summarized in a first-author manuscript (under review, 2025).• Flow Cytometry Panels: Established and optimized multi-parameter flow cytometry assays to profile TME characteristics and molecular signatures.• In Vivo Pharmacology: Executed multi-arm studies (~150 animals/experiment) with reproducibility and compliance, generating robust efficacy and PK/PD datasets.• Scientific Communication: Presented research at internal/external symposia and led cross-site forums to harmonize preclinical workflows across discovery teams.

EDUCATION

N/A

Purdue University

Doctor of Philosophy - PhD

2013 — 2015

Delhi University

Master's degree, Biomedical Sciences

2010 — 2013

Hindu College, University of Delhi

Bachelor's degree (Honours), Zoology/Animal Biology

ABOUT SRISHTI CHAKRAVORTY

I am a scientist passionate about translating complex biology into impactful therapies. Over the past 9 years, including 3 in pharma, I have combined molecular and cellular biology, cancer immunology, in vitro mechanistic biology, and in vivo pharmacology to advance preclinical and translational research.During my Ph.D. in Biochemistry at Purdue University, I investigated host-pathogen interactions in viral cancers, applying RNA-seq, molecular, and cell-based assays to uncover biomarkers and therapeutic targets. Building on this foundation, I joined Merck & Co, in 2022 where my postdoctoral project has focused on understanding antibody-drug conjugate (ADC) mechanism of action. In this role, I have engineered target-expressing cell lines, developed internalization and potency assays, built tumor models, and applied high-dimensional flow cytometry to reveal how ADC payloads reshape the tumor microenvironment. I also designed and executed large-scale in vivo studies (typically with cohort sizes of ~150 animals), spanning implantation, dosing, and PK/PD analyses to generate translational insights, culminating in a first-author publication.I value collaboration and mentoring as much as I enjoy the science itself, from training students and organizing symposia to leading the Biochemistry graduate student organization. Sharing knowledge and solving problems alongside diverse teams is where I thrive. With multiple peer-reviewed publications, I enjoy presenting research and helping programs gain visibility across functions. 🤝 I am eager to apply my blend of technical expertise, curiosity, and collaboration to drug discovery and translational research in oncology, immunology, and related therapeutic areas. Actively seeking opportunities and would welcome connecting with those hiring, collaborating, or sharing a commitment to advancing cancer and immune-based therapeutics. Open to relocation for the right scientific opportunity.#Opentowork

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Srishti Chakravorty — Email, Phone Number & Contact Info | Unifers